Actinium Pharmaceuticals to Present ATNM-400 Program Update at SNMMI 2026 Conference on May 31-June 2 and Provides NYSE American Listing Standards Notice

Source · https://www.prnewswire.com/news-releases/actinium-pharmaceuticals-to-present-atnm-400-program-update-at-snmmi-2026-conference-on-may-31-june-2-and-provides-nyse-american-listing-standards-notice-302786103.html

Read source

Actinium Pharmaceuticals to Present ATNM-400 Program Update at SNMMI 2026 Conference on May 31-June 2 and Provides NYSE American Listing Standards Notice

Search tags

What matters in this story

Actinium Pharmaceuticals received a notice from NYSE American stating it is not in compliance with continued listing standards due to insufficient stockholders' equity. — Failure to meet listing requirements introduces significant delisting risk and reflects a weak balance sheet.

-0.60

The company must submit a compliance plan by June 26, 2026, to avoid the commencement of delisting proceedings. — This creates a tight near-term deadline and uncertainty regarding the company's ability to raise capital or restructure.

-0.40

Actinium will present new data on its ATNM-400 program for prostate and non-small cell lung cancer at the SNMMI 2026 Conference. — Clinical data presentations can serve as positive catalysts for biotech stocks, though this is preliminary data.

+0.30

Actinium Pharmaceuticals to Present ATNM-400 Program Update at SNMMI 2026 Conference on May 31-June 2 and Provides NYSE American Listing Standards Notice

What matters in this story

Menarini Group presenta nuevos datos del estudio ELEVATE de elacestrant en combinación con capivasertib

Actinium Pharmaceuticals to Present ATNM-400 Program Update at SNMMI 2026 Conference on May 31-June 2 and Provides NYSE American Listing Standards Notice

What matters in this story

Menarini Group presenta nuevos datos del estudio ELEVATE de elacestrant en combinación con capivasertib

Sentiment in this article

Relationships in this article

Analytical profile by cluster

Top impact dimensions

Most positively impacted

Most negatively impacted

CelLBxHealth signs master services agreement with AstraZeneca

PeproMene Bio anuncia una presentación oral en EHA 2026 donde destacará el PMB-CT01 en linfomas de células B

Innovent Biologics shares rise 10% after pact with Pfizer of up to $10.5 billion

Actinium Pharmaceuticals Receives Two Patent Allowances Spanning Its Actimab-A and Iomab-ACT Programs

Corcept Presents New Data at ASCO 2026: Lifyorli™ Overall Survival Across All Subgroups of Patients with Platinum-Resistant Ovarian Cancer, Including Those with Recent Taxane Exposure

Actinium Pharmaceuticals to Present ATNM-400 Program Update at SNMMI 2026 Conference on May 31-June 2 and Provides NYSE American Listing Standards Notice

What matters in this story

Next reads from the same story arc

Menarini Group presenta nuevos datos del estudio ELEVATE de elacestrant en combinación con capivasertib

Actinium Pharmaceuticals to Present ATNM-400 Program Update at SNMMI 2026 Conference on May 31-June 2 and Provides NYSE American Listing Standards Notice

What matters in this story

Next reads from the same story arc

Menarini Group presenta nuevos datos del estudio ELEVATE de elacestrant en combinación con capivasertib

Sentiment in this article

Relationships in this article

Analytical profile by cluster

Top impact dimensions

Most positively impacted

Most negatively impacted

CelLBxHealth signs master services agreement with AstraZeneca

PeproMene Bio anuncia una presentación oral en EHA 2026 donde destacará el PMB-CT01 en linfomas de células B

Innovent Biologics shares rise 10% after pact with Pfizer of up to $10.5 billion

Actinium Pharmaceuticals Receives Two Patent Allowances Spanning Its Actimab-A and Iomab-ACT Programs

Corcept Presents New Data at ASCO 2026: Lifyorli™ Overall Survival Across All Subgroups of Patients with Platinum-Resistant Ovarian Cancer, Including Those with Recent Taxane Exposure